For Collaborators
We pursue collaborations that bring complementary biological insight, experimental capabilities, or quantitative methods to a defined question in glioblastoma. The laboratory’s contribution is a research program spanning patient-derived tumor systems, human brain microenvironments, cellular-state biology, and longitudinal functional analysis. We are particularly interested in problems for which tumor–host interactions may change the mechanism or therapeutic consequence inferred from an isolated-cell assay.
Academic collaborations may involve a proposed molecular dependency, a neural or immune interaction, an experimental therapeutic, or a technology that makes a previously inaccessible behavior measurable. We work with collaborators to select the biological setting and the perturbations that can establish mechanism, then determine whether a finding persists across patient-derived tumors or more integrated models. The relevant contribution may be access to a specific system, but the intended outcome is a joint scientific result rather than use of a model without a clearly articulated question.
Computational collaborations include causal and mechanistic inference from single-cell or spatial measurements, analysis of live cellular activity, agent-based modeling, and prediction of experimentally measured treatment responses. We are interested in methods that can guide the next experiment and whose performance can be evaluated on data that were not used to construct them. The laboratory can contribute deeply characterized experimental systems and biological interpretation; the complementary opportunity is to develop models that account for heterogeneity, context, and adaptation rather than average them away.
Published protocols provide a starting point for groups establishing GLICO-based experiments. Requests for biological materials, unpublished datasets, collaborative screening, or further model development are considered in relation to scientific fit, capacity, consent requirements, and institutional agreements. Commercial development and licensing inquiries should be directed through Weill Cornell Medicine Enterprise Innovation, whose GLICO technology page provides the institutional route.
For academic and computational inquiries, please contact haf9016@med.cornell.edu with a concise description of the question, the resources or expertise your group would contribute, and the proposed role of the laboratory. Please identify any confidentiality or intellectual-property considerations before transmitting proprietary information.
Weill Cornell Medicine Fine Lab
413 E 69th Street, 9th floor New York, NY 10021
Phone: (646) 962-6851